Designing immunotherapy for brain cancer

Designing immunotherapy for brain cancer

Project details

Chimeric antigen receptor therapy is an innovative way to co-opt and potentially tailor T cells to kill cancer cells, particularly where all other treatments have failed. The impressive success of CAR T cell therapy in clinical trials for some cancer types means that further applications have been sought with accelerating pace.

This project will investigate specific features of CAR T cell biology that are currently blocking successful translation to treating brain cancer. The project will utilise a combination of techniques including molecular biology, cellular biology, immunological assays and in vivo tumour models, to examine the efficacy of an engineered CAR T cell in models of brain cancer.


Dr Misty Jenkins

Dr Misty Jenkins at a microscope
Laboratory Head
Ryan Cross profile photo
Immunology division

Project Type: